Application Note: Characterizing T-cell immune responses against SARS-COV-2 with Ella
15 October 2020

Immune cell therapy has revolutionized the way we think about treating cancer, but could this type of immunotherapy be beneficial in an infectious disease setting? The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and its associated coronavirus disease 2019 (COVID-19) has certainly presented researchers with an opportunity to evaluate its therapeutic utility.